Full-Time

Senior Quality Engineer-Combination Products

Tech Transfer & Commercial

Posted on 4/16/2025

Gilead Sciences

Gilead Sciences

10,001+ employees

Biopharmaceutical company developing innovative medicines

Compensation Overview

$136.3k - $176.4k/yr

+ Bonus + Stock-based long-term incentives

Senior

Company Historically Provides H1B Sponsorship

San Mateo, CA, USA

Category
QA & Testing
Quality Assurance
Required Skills
Risk Management
Requirements
  • Must have 6+ years of experience in the medical device industry and a Bachelor’s degree in science or engineering related field, or equivalent OR 4+ years of relevant experience with a Master’s degree.
  • Demonstrates in-depth knowledge of Quality principles, concepts, industry practices, and standards.
  • Quality experience in both clinical and commercial products.
  • Strong project management and process improvement skills.
  • Demonstrates understanding of U.S. and international quality systems regulations/standards to adopt best in class systems/processes and drive continuous improvement initiatives.
Responsibilities
  • Provide Quality oversight for the Commercial stage, including Design Transfer
  • Evaluate design changes and provide quality input to support continuous improvement initiatives.
  • Maintain compliance with global Risk Management processes in accordance with ISO 14791 and other applicable standards. Work cross-functionally with Subject Matter Experts from R&D, Clinical, and Operations to ensure the risk process is applied comprehensively.
  • Develop key relationships and interface extensively with internal stakeholders and contract manufacturers to address and resolve complex technical related drug device combination product, process and quality issues.
  • Ensure that changes to commercial products are conducted in accordance with FDA QSR/QMSR, ISO 13485, and other applicable standards.
  • Participate in annual product reviews and perform periodic review and update of DHF and RMF.
  • Executes changes to quality processes to ensure conformance and continuous improvement.
  • Writes and/or implements changes to controlled documents (e.g., SOPs, Specifications, WIs, etc.) as needed.
  • Review design inputs, outputs, and verification/validation results.
  • Evaluate, develop, and execute protocols for Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ).
  • Analyze process data and ensure processes are capable and in control.
  • Maintains expertise in both current and emerging requirements and quality trends as they relate to Pharmaceuticals, Medical Devices, and Combination Products worldwide.
  • Work with management and department personnel to achieve goals and strategic initiatives.
  • Supports due diligence and internal or external audits/inspections as needed.
  • Create and provide Quality training as needed for cross functional stake holders and CMOs.
  • Support complaints investigations and filter information back to the design and development team and CMOs.
  • Create/revise/execute SOPs to support combination product quality governance in the commercial stage.
  • Stay abreast of evolving regulatory requirements and ensure commercial products comply with applicable standards.
Desired Qualifications
  • Previous experience with combination devices is preferred (i.e., Autoinjectors, co-packaged kits, pre-filled syringes).
  • Knowledge of Six Sigma, Define-Measure-Analyze-Improve-Control (DMAIC) methodology, performance measures and quality improvement statistical is preferred.
  • Knowledge of ISO 14971 Risk Management tools (e.g., Hazard Analysis / or Failure Mode Effects Analysis (FMEA)) is preferred.
  • Certification by ASQ (Certified Quality Auditor, Certified Quality Engineer, and Certified Quality Manager) or other industry-recognized professional organizations is preferred.

Gilead Sciences is a biopharmaceutical company that develops and sells medicines for various serious health conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company conducts extensive research and development to create new therapies, which are then approved by regulatory authorities before being marketed to healthcare providers, hospitals, and pharmacies. Gilead stands out from its competitors by investing heavily in R&D and forming strategic partnerships, such as with SAP Ariba, to improve its supply chain and ensure sustainable practices. The company's goal is to enhance health equity and access to care, working with communities globally to remove barriers to healthcare and make its medicines available to those in need.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • Lenacapavir's yearly dosage improves patient adherence and outcomes.
  • Partnerships with LEO Pharma and GRYT Health expand Gilead's therapeutic offerings.
  • Manufacturing efficiencies strengthen Gilead's position in CAR-T cell therapy.

What critics are saying

  • AI-driven competitors may erode Gilead's market share and innovation lead.
  • Layoffs could disrupt Gilead's operations and strategic decision-making.
  • Stigma around diseases like lung cancer may hinder market acceptance of treatments.

What makes Gilead Sciences unique

  • Gilead's lenacapavir reformulation offers a once-yearly HIV prevention option.
  • Strategic partnerships enhance Gilead's R&D capabilities and market reach.
  • Gilead's focus on health equity initiatives sets it apart in the biopharma industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Company News

SFist
Apr 2nd, 2025
April Fool's Day Around the Bay: Bob Lee's Family Has Sued His Convicted Killer Nima Momeni

Foster City-based HIV drug company Gilead Sciences is laying off nearly 150 people, and the job cuts are significant among senior members of the company's management.

Labiotech
Mar 27th, 2025
12 Ai Drug Discovery Companies You Should Know About

Newsletter Signup - Under Article / In Page"*" indicates required fields Artificial intelligence (AI) has taken the biotech industry by storm, allowing companies to speed up the drug discovery process while also making it more cost-effective. With so many companies in the industry now embracing the technology, we take a look at 12 AI drug discovery companies. The COVID-19 pandemic revealed AI to be an essential tool in helping to find treatments and vaccines with greater speed and precision. Since then, there have been several drug discovery breakthroughs for AI within the biopharma industry, from helping to quickly and efficiently discover a new antibiotic called abaucin to combat a multi-drug resistant bacteria, to fully discovering and designing a drug that has entered clinical trials. Here are 12 AI drug discovery companies currently making great strides with their technology. Anima Biotech Technology: mRNA biology modulators Disease areas: Immunology, oncology and neuroscienceRecent news: Announced promising preclinical data for lead pulmonary fibrosis candidate Anima Biotech’s AI drug discovery technology is built around its mRNA Lightning.AI platform, which images hundreds of cellular pathways in both healthy and diseased cells to train disease-specific AI models, making use of neural networks to help these models distinguish between healthy and diseased cells and identify dysregulated pathways. These pathways are subsequently analyzed to uncover novel targets backed by experimental validation. Anima currently has 20 preclinical candidates being evaluated for immunology, oncology, and neuroscience indications, with its most advanced candidate indicated for the treatment of lung fibrosis. The company announced in February 2024 that this candidate had shown promising preclinical results and could open up new avenues for treating patients with idiopathic pulmonary fibrosis. The AI drug discovery company also has ongoing collaborations with several pharma giants. After initially partnering with Eli Lilly in 2018 and Takeda in 2021, its most recent partnership was formed with AbbVie in 2023 for the discovery and development of mRNA biology modulators against oncology and immunology targets. Atomwise Technology: TYK2 inhibitor  Disease area: Autoimmune and autoinflammatory diseasesRecent news: Published results showcasing AtomNet’s ability for drug discoveryAtomwise is leveraging the power of AI in an attempt to revolutionize small molecule drug discovery

Charities.org
Mar 25th, 2025
Sustainability News provided by 3BL

Gilead recently partnered with GRYT Health to host a New Lens on Lung Cancer workshop where people living with lung cancer and their loved ones shared their experience with stigma.

CSR Company
Mar 18th, 2025
Gilead Sciences Ranked in Top Five Most JUST List for Biopharma Companies

Gilead Sciences ranked in top five Most JUST list for biopharma companies.

Pipeline Review
Mar 12th, 2025
First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet

First clinical data for Gilead's investigational Once-Yearly Lenacapavir for HIV Prevention presented at CROI 2025 and published in The Lancet.

INACTIVE